Compass Therapeutics Inc

CMPX | $1.49 -1.97% -2.01% 150K

(0.0% 1d) (-25.9% 1m) (-42.4% 1y) (0.0% 2d) (2.0% 3d) (3.4% 7d) (-32.34% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 205,007,865

Sec Filling | Patents | 26 employees

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond

add to watch list Paper trade email alert is off

BioRestorative Therapies, Inc.

BRTX | $1.26 -5.97% -6.35% 75K

Professional, Scientific, and T...

(0.0% 1d) (-4.3% 1m) (-65.4% 1y) (0.0% 2d) (-2.9% 3d) (-5.0% 7d) (48.32% volume)
Earnings Calendar:
Market Cap: $ 8,530,098
http://www.biorestorative.com/
Sec Filling | Patents | 5 employees

(US) biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas

injection t-cell

add to watch list Paper trade email alert is off

Intertek Group plc

IKTSY | $62.1945 -12.21% 2.4K

Professional, Scientific, and T...

(0.0% 1d) (-0.8% 1m) (19.7% 1y) (0.0% 2d) (0.6% 3d) (2.3% 7d) (-4.84% volume)
Earnings Calendar:
Market Cap: $ 10,037,764,837
http://www.intertek.com/
Sec Filling | Patents | n/a employees

(United Kingdom)

add to watch list Paper trade email alert is off